Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
1(17%)
Results Posted
0%(0 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_3
3
50%
Ph phase_1
3
50%

Phase Distribution

3

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 3Large-scale testing
3(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(3)
Terminated(1)
Other(1)

Detailed Status

Completed3
unknown1
Terminated1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (50.0%)
Phase 33 (50.0%)

Trials by Status

completed350%
unknown117%
terminated117%
recruiting117%

Recent Activity

1 active trials
Showing 5 of 6
recruitingphase_3

A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).

NCT03851640
completedphase_1

A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics

NCT03776968
terminatedphase_3

HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT03850795
unknownphase_3

HC-1119 Adjuvant Treatment for Hospitalized COVID-19 Patients

NCT04986176
completedphase_1

A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients.

NCT03774056
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT03851640Phase 3

A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Recruiting
NCT03776968Phase 1

A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics

Completed
NCT03850795Phase 3

HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Terminated
NCT04986176Phase 3

HC-1119 Adjuvant Treatment for Hospitalized COVID-19 Patients

Unknown
NCT03774056Phase 1

A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients.

Completed
NCT03778047Phase 1

A Study Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6